Peptide And Oligonucleotide CDMO Market Size To Reach $8.14 Billion By 2033

Peptide And Oligonucleotide CDMO Market Growth & Trends

The global peptide and oligonucleotide CDMO market size is expected to reach USD 8.14 billion by 2033, registering a CAGR of 12.8% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growing recognition of peptides and oligonucleotides as valuable therapeutic agents for various diseases is fueling the demand for CDMO services. Moreover, the increasing pipeline of peptides and oligonucleotide therapeutics and the growing penetration of CDMOs in the field are a few of the factors driving the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. These companies offer various services related to peptide and oligonucleotide development, data interpretation, sample analysis, and clinical trial support. The market is characterized by fierce competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

The growing investment by major companies in the development and manufacturing of peptides and oligonucleotide-based therapeutics is one of the prominent factors supporting the growth of the market. For instance, in September 2023, CordenPharma announced the expansion of its commercial peptide production capabilities through the enhancement of facilities at CordenPharma Colorado, which now stands as the world's largest Solid-Phase Peptide Synthesis (SPPS) manufacturing facility. Additionally, in September 2023, CombiGene selected AmbioPharm as the CDMO partner for their peptide-based pain project, COZY01, which also involves Zyneyro.

The COVID-19 pandemic moderately impacted the market. The early stages of the COVID-19 pandemic had a notable impact on clinical trials, as a result of travel restrictions, disruptions in the supply chain, and setbacks in clinical trials. Nonetheless, it also presented prospects, notably the heightened emphasis on antiviral peptides and the swift creation of mRNA vaccines. Furthermore, there has been a substantial increase in collaborations and partnerships across biopharmaceutical companies with an aim to boost the production of peptide-based therapeutics.

 Request a free sample copy or view report summary: Peptide And Oligonucleotide CDMO Market Report

Peptide And Oligonucleotide CDMO Market Report Highlights

• On the basis of product segment, the market is classified into peptides and oligonucleotides. The peptides segment accounted for the largest revenue share in the API CDMO industry of 67.48% in 2024.

• On the basis of service segment, the market is segregated into contract development and contract manufacturing. The contract manufacturing segment held the largest share in the market in 2024.

• On the basis of the end use segment, the market is segregated into pharmaceutical companies, biopharmaceutical companies, and others.

• The biopharmaceutical companies segment is anticipated to grow at the fastest CAGR during the forecast period. This growth is due to the rapid expansion of biotech firms specializing in innovative Peptide and Oligonucleotide therapeutics, particularly in personalized medicine and gene therapy.

• North America accounted for the largest revenue share of 36.37% in peptide and oligonucleotide CDMO market in 2024

Peptide And Oligonucleotide CDMO Market Segmentation

Grand View Research has segmented the global Peptide And Oligonucleotide CDMO market report based on type, security, end use, and region:

Peptide And Oligonucleotide CDMO Product Outlook (Revenue, USD Million, 2021 - 2033)

• Peptides

• Oligonucleotides

Peptide And Oligonucleotide CDMO Service Outlook (Revenue, USD Million, 2021 - 2033)

• Contract Development

• Contract Manufacturing

Peptide And Oligonucleotide CDMO End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Pharmaceutical Companies

• Biopharmaceutical Companies

• Others

Peptide And Oligonucleotide CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players in Peptide And Oligonucleotide CDMO Market

• PolyPeptide Group

• STA Pharmaceutical Co. Ltd.

• Bachem

• Creative Peptides

• Aurigene Pharmaceutical Services Ltd.

• Merck KGaA

• EUROAPI

• Curia Global, Inc.

• CordenPharma

• Sylentis, S.A.